FDA sets May 1 deadline for UniQure's Huntington's gene therapy; Inovio's Voceryq approved for RRP; AbbVie wins Botox IRA ...
Karyopharm files for Chapter 11 and plans a merger with Gamida Cell parent Ayrmid, backed by $55M in DIP financing; shares fall 84%.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results